BRIEF-UL Solutions Inc Says Currently Estimated IPO Price Per Share Of Class A Common Stock Will Be Between $26 and $29-March 2024-www.financetom.com

BRIEF-UL Solutions Inc Says Currently Estimated IPO Price Per Share Of Class A Common Stock Will Be Between $26 and $29

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

BRIEF-UL Solutions Inc Says Currently Estimated IPO Price Per Share Of Class A Common Stock Will Be Between $26 and $29

Apr 2, 2024 4:48 AM

April 2 (Reuters) - UL Solutions Inc:

* UL SOLUTIONS INC SAYS CURRENTLY ESTIMATED THAT IPO PRICE

PER

SHARE OF CLASS A COMMON STOCK WILL BE BETWEEN $26.00 AND $29.00

- SEC FILING

* UL SOLUTIONS INC SEES IPO OF 28 MILLION SHARES OF CLASS A

COMMON

STOCK - SEC FILING

* UL SOLUTIONS INC - ADDS AMERIVET SECURITIES, BANCROFT

CAPITAL,

CABRERA CAPITAL MARKETS, LOOP CAPITAL MARKETS AND R SEELAUS & CO

AS UNDERWRITERS TO IPO

* UL SOLUTIONS INC: NORGES BANK INVESTMENT MANAGEMENT,

INDICATED

INTEREST IN PURCHASING UPTO $75 MILLION SHARES OF CLASS A COMMON

STOCK IN THIS IPO PRICE

Source text for Eikon:

Further company coverage:

Previous page： Rare Earth Stocks Rise Pre-Bell After China Tightens Export Controls Next page： Ligand Partner SQ Innovation Gets FDA Approval for At-Home Edema Treatment for Heart Failure Patients

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Rare Earth Stocks Rise Pre-Bell After China Tightens Export Controls

Oct 9, 2025

08:20 AM EDT, 10/09/2025 (MT Newswires) -- Rare earth stocks, including MP Materials ( MP ) , Energy Fuels ( UUUU ) , and NioCorp Developments ( NB ) , were up premarket Thursday after China's Ministry of Commerce said it established new export controls on rare earth-related technologies. New regulations prohibit the export of technologies used to mine and...

Ligand Partner SQ Innovation Gets FDA Approval for At-Home Edema Treatment for Heart Failure Patients

Oct 9, 2025

08:19 AM EDT, 10/09/2025 (MT Newswires) -- Ligand Pharmaceuticals ( LGND ) said Thursday its partner SQ Innovation received US Food and Drug Administration approval for Lasix Onyu, an at-home furosemide treatment for edema in adults with chronic heart failure that can be injected under the skin. The drug-device uses a high-concentration furosemide delivered via a small Infusor with a...

Cineplex Reports Box Office Revenues of $37.7 Million for September

Oct 9, 2025

08:18 AM EDT, 10/09/2025 (MT Newswires) -- Cineplex ( CPXGF ) , a Canada entertainment and media company, Thursday reported box office revenues of $37.7 million for September 2025. The company said that the month delivered a series of franchise milestones at the box office, with The Conjuring: Last Rites leading the month with an $84 million debut, marking the...

Alterity Says Data Showed Potential Multiple System Atrophy Drug Slowed Disease Progression in Phase 2 Study

Oct 9, 2025

08:19 AM EDT, 10/09/2025 (MT Newswires) -- Alterity Therapeutics ( ATHE ) said Thursday that data from a 77-patient phase 2 clinical trial of its drug ATH434 for the potential treatment of multiple system atrophy slowed disease progression. Chief Executive David Stamler said the ongoing double-blind trial showed a stabilization of orthostatic hypotension, a symptom of multiple system atrophy, at...